Richard H. Hughes, IV, and William Walters, attorneys in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, co-authored an article in Health Affairs, titled “Medicare Coverage of Antiobesity Medicines.” (Read the full version – subscription required.)
Following is an excerpt:
Any serious conversation about glucagon-like peptide-1 receptor agonists (GLP-1s) should include consideration of the benefits experienced by patients, as well as cost savings and the broader economic and social benefits achieved.
